Juniper Biosciences received Breakthrough Therapy designation from the FDA for its Phase III program JBS-003 (F-MISO) in partnership with MSKCC.
Public source
Publisher name
Public post
We are thrilled to announce that the FDA has granted Breakthrough Therapy designation to our Phase III program, JBS-003 (F-MISO), in partnership with MSKCC. This designa…
Company
Juniper Biosciences
Developing innovative radiopharmaceutical products for the future of patient care
- Industry
- Pharmaceutical Manufacturing
- Location
- Bedminster, US
- Company size
- 2–10 employees
About Juniper Biosciences
Juniper Biosciences is a radiopharmaceutical company focused on developing its pipeline of innovative products
See moreLatest activity
Latest activity from Juniper Biosciences
3 signals
Legal & Regulatory
Juniper Biosciences received Breakthrough Therapy Designation for its JBS-003 program in partnership with MSKCC, which was pioneered by Dr. Nancy Lee.
Legal & Regulatory
Juniper Biosciences received Breakthrough Therapy designation from the FDA in partnership with MSKCC for its Phase III program.
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
MERIT CRO
MERIT CRO received Breakthrough Therapy and Fast Track designations from the FDA for 68Ga-NYM096, a PET imaging agent for clear cell renal cell carcinoma showing 100% sensitivity and 96% accuracy in differentiating clear cell renal cell carcinoma from non-ccRCC lesions without invasive tissue sampling.
Legal & Regulatory
Anticancer Bioscience
Anticancer Bioscience received regulatory clearance for the Investigational New Drug (IND) application for JMBI-001 in China, enabling the program to advance toward a first-in-human Phase 1 clinical study.
Legal & Regulatory
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited positively engaged with the U.S. FDA on a New Drug Application (NDA) pathway that would support new product reimbursement and broaden patient access to ⁶⁸Ga-PSMA-PET imaging.
Legal & Regulatory
SOTIO Biotech
SOTIO Biotech has received FDA approval for its investigational new drug (IND) application for SOT106, enabling a first-in-human Phase 1/2 trial in patients with osteosarcoma and soft tissue sarcoma.
Legal & Regulatory
SOFIE